BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen
The Pharma Data
JANUARY 13, 2021
Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products.
Let's personalize your content